Marker Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Marker Therapeutics, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Marker Therapeutics has little or no product revenue yet; it used $10m of cash in the twelve months to June 2026. The diluted share count is up 73.3% on a year earlier, which dilutes existing holders. It passes 2 of our 2 financial-health checks.
Our model value for Marker Therapeutics is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Marker Therapeutics, Inc.'s trailing-twelve-month revenue fell 30.7% year on year, with a free-cash-flow margin of -200.5%.
Current signal Revenue growth accelerating: TTM revenue growth rose to -30.7% (+15.5pp vs the prior quarter).
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
| At fiscal year end | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Now |
|---|---|---|---|---|---|---|---|---|---|---|
| Share price | $39.20 | $55.50 | $28.80 | $14.50 | $9.50 | $2.70 | $5.50 | $3.11 | $1.49 | $0.90 |
| Market value | $74m | $106m | $131m | $68m | $73m | $23m | $48m | $28m | $23m | $16m |
| + Net debt (− = net cash) | −$5m | −$62m | −$44m | −$21m | −$42m | −$12m | −$15m | −$19m | −$16m | −$15m |
| Enterprise value | $69m | $44m | $87m | $47m | $30m | $11m | $33m | $9m | $7m | $710719 |
| Multiples | ||||||||||
| Price / sales | n/m | n/m | n/m | 136.4x | 58.5x | 6.4x | 14.6x | 4.2x | 6.4x | 4.0x |
| Price / earnings | — | — | — | — | — | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.56 | +26% | $4m | +20% |
| Next | −$0.53 | +6% | $20m | +376% |
The consensus EPS forecast for the current fiscal year is −18.1% on 90 days ago. In the last 30 days, 2 analysts raised Marker Therapeutics, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.69 | −$0.76 |
| 60 days ago | −$0.56 | −$0.53 |
| 30 days ago | −$0.56 | −$0.53 |
| 7 days ago | −$0.56 | −$0.53 |
| Now | −$0.56 | −$0.53 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.18 | −$0.09 | +50.0% |
| Mar 2026 | −$0.19 | −$0.16 | +15.8% |
| Dec 2025 | −$0.19 | −$0.04 | +79.0% |
| Sept 2025 | −$0.21 | −$0.12 | +42.9% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| MRKR | −35% | −72% | +104% | −44% | −52% | −40% |
| Industry peers (median) | −36% | −56% | −18% | −28% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| MRKR | 33% | 33% | 67% | 25% | 33% | 36% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| MRKR | −73% | −76% | −82% | −58% | −74% | −59% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 99% from June 18, 2018 to March 31, 2023. Getting back needed a 17266% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| March 19, 2026 | 0.0% | −1.7% | +0.7% | +24.6% |
| November 14, 2025 | +6.7% | −0.9% | +19.1% | +42.7% |
| March 31, 2025 | −10.2% | +1.0% | −20.5% | −6.3% |
| November 14, 2024 | −15.7% | −1.9% | −19.0% | +13.5% |
| August 14, 2024 | −6.2% | +2.0% | +6.2% | −18.3% |
| May 15, 2024 | +3.0% | +1.0% | −1.0% | +4.5% |
| March 26, 2024 | −10.3% | +0.7% | −6.0% | −9.7% |
| November 9, 2023 | −10.5% | +0.8% | −9.5% | +54.4% |
| August 14, 2023 | +23.4% | −0.6% | +36.8% | +12.6% |
| March 22, 2023 | −46.6% | −1.4% | −51.7% | −44.9% |
| November 10, 2022 | 0.0% | +6.5% | −7.9% | −21.1% |
| August 11, 2022 | −20.4% | +1.7% | −24.5% | −8.2% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q2 | $3.8M |
| FY23 Q3 | $3M |
| FY23 Q4 | $3.3M |
| FY24 Q1 | $3.3M |
| FY24 Q2 | $3.7M |
| FY24 Q3 | $5.4M |
| FY24 Q4 | $6.6M |
| FY25 Q1 | $5.7M |
| FY25 Q2 | $5.4M |
| FY25 Q3 | $4.7M |
| FY25 Q4 | $3.5M |
| FY26 Q1 | $3.9M |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q4 | -5.8% |
| FY24 Q1 | -12.2% |
| FY24 Q2 | -0.8% |
| FY24 Q3 | 79.0% |
| FY24 Q4 | 99.1% |
| FY25 Q1 | 71.5% |
| FY25 Q2 | 44.6% |
| FY25 Q3 | -13.0% |
| FY25 Q4 | -46.2% |
| FY26 Q1 | -30.7% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q2 | -460.9% |
| FY23 Q3 | -487.2% |
| FY23 Q4 | -440.4% |
| FY24 Q1 | -386.1% |
| FY24 Q2 | -295.0% |
| FY24 Q3 | -188.9% |
| FY24 Q4 | -168.7% |
| FY25 Q1 | -237.5% |
| FY25 Q2 | -303.3% |
| FY25 Q3 | -342.5% |
| FY25 Q4 | -397.6% |
| FY26 Q1 | -334.6% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q2 | -716.1% |
| FY23 Q3 | -676.2% |
| FY23 Q4 | -496.5% |
| FY24 Q1 | -433.3% |
| FY24 Q2 | -292.4% |
| FY24 Q3 | -158.9% |
| FY24 Q4 | -165.5% |
| FY25 Q1 | -220.7% |
| FY25 Q2 | -202.0% |
| FY25 Q3 | -315.6% |
| FY25 Q4 | -338.7% |
| FY26 Q1 | -200.5% |
| Fiscal year | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||
| Revenue | 0 | 0 | 0 | 1 | 1 | 4 | 3 | 7 | 4 | 4 |
| EBITDA | — | −148 | −22 | −28 | −37 | −17 | — | — | — | — |
| Operating income | −11 | −148 | −23 | −29 | −39 | −20 | −15 | −11 | −13 | −13 |
| Net income | −11 | −148 | −21 | −29 | −42 | −30 | −8 | −11 | −12 | −11 |
| Diluted EPS | −$5.80 | −$77.50 | −$4.70 | −$6.10 | −$5.47 | −$3.58 | −$0.94 | −$1.19 | −$0.79 | −$0.63 |
| Growth (year on year) | ||||||||||
| Revenue | — | +12.5% | +3.5% | +134.5% | +148.3% | +183.0% | −5.8% | +99.1% | −46.2% | −30.7% |
| Margins | ||||||||||
| EBITDA margin | — | <−999% | <−999% | <−999% | <−999% | −483.9% | — | — | — | — |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | −563.3% | −440.4% | −168.7% | −363.5% | −334.6% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | −851.9% | −248.8% | −162.8% | −343.0% | −275.9% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | <−999% | −767.7% | −496.5% | −165.5% | −338.7% | −200.5% |
| Cash flow | ||||||||||
| Cash from operations | −8 | −14 | −18 | −20 | −27 | −27 | −16 | −11 | −12 | −8 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −8 | −15 | −19 | −20 | −27 | −27 | −16 | −11 | −12 | −8 |
| Stock-based pay | 3 | 16 | 5 | 5 | 6 | 3 | 1 | 0 | 1 | 0 |
| Free cash flow after stock pay | −11 | −31 | −24 | −25 | −33 | −30 | −17 | −11 | −13 | −8 |
| Balance sheet | ||||||||||
| Cash | 5 | 62 | 44 | 21 | 42 | 12 | 15 | 19 | 16 | 15 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −5 | −62 | −44 | −21 | −42 | −12 | −15 | −19 | −16 | −15 |
| Diluted shares | 2m | 2m | 5m | 5m | 8m | 8m | 9m | 9m | 15m | 17m |
| Returned to shareholders | ||||||||||
| Buybacks | 0 | 0 | — | — | — | — | — | — | — | — |
| Total returned | 0 | 0 | — | — | — | — | — | — | — | — |
| Quarter | 2024 Q2 Jun 2024 | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 1,169 | 1,926 | 2,252 | 349 | 861 | 1,233 | 1,103 | 752 |
| Operating income | −2,308 | −2,400 | −3,861 | −4,958 | −5,122 | −2,137 | −1,884 | −4,073 |
| Net income | −2,193 | −2,308 | −3,838 | −4,446 | −4,016 | −1,999 | −1,703 | −3,179 |
| Diluted EPS | −$0.25 | −$0.26 | −$0.42 | −$0.40 | −$0.29 | −$0.12 | −$0.04 | −$0.16 |
| Growth (year on year) | ||||||||
| Revenue | +53.3% | +647.7% | +113.1% | −71.9% | −26.3% | −36.0% | −51.0% | +115.3% |
| Net income | −187.2% | — | — | — | — | — | — | — |
| Diluted EPS | −186.2% | — | — | — | — | — | — | — |
| Margins | ||||||||
| Operating margin | −197.4% | −124.6% | −171.5% | <−999% | −594.8% | −173.3% | −170.7% | −541.8% |
| Net margin | −187.5% | −119.8% | −170.4% | <−999% | −466.3% | −162.1% | −154.4% | −423.0% |
| Free-cash-flow margin | −305.1% | 62.2% | −208.9% | <−999% | −218.1% | −221.9% | −172.2% | −186.8% |
| Cash flow | ||||||||
| Cash from operations | −3,568 | 1,197 | −4,703 | −5,500 | −1,878 | −2,736 | −1,900 | −1,404 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −3,568 | 1,197 | −4,703 | −5,500 | −1,878 | −2,736 | −1,900 | −1,404 |
| Stock-based pay | 63 | 53 | 51 | 379 | 14 | 33 | 111 | 178 |
| Free cash flow after stock pay | −3,631 | 1,144 | −4,754 | −5,879 | −1,892 | −2,769 | −2,011 | −1,583 |
| Last 12 months unless stated | MRKR | DBVT | DYAI | ALGS | CAMP | CRIS | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $4m | $4m | $4m | $4m | $4m | $4m | $55m |
| Revenue growth, last 12 months | −30.7% | −31.6% | −8.0% | 19.4% | 40.2% | −62.2% | 12.2% |
| Revenue growth, 3-year average | 1.4% | −11.6% | 3.4% | −5.5% | — | −25.0% | 13.1% |
| Revenue growth, latest quarter | 115.3% | −42.9% | −0.6% | −100.0% | 18.8% | −100.0% | 10.2% |
| Operating margin | −334.6% | <−999% | −195.1% | <−999% | <−999% | −203.2% | −191.1% |
| Operating margin, 3-year average | −319.4% | <−999% | −257.9% | <−999% | — | −341.2% | −361.6% |
| Net margin | −275.9% | <−999% | −200.5% | <−999% | <−999% | −490.3% | −172.8% |
| Cash from operations / revenue | −200.5% | <−999% | −194.7% | <−999% | −678.2% | −709.0% | −168.8% |
| Free-cash-flow margin | −200.5% | <−999% | — | <−999% | −681.2% | −709.0% | −168.1% |
| Free-cash-flow margin, 3-year average | −284.8% | <−999% | — | <−999% | — | −465.5% | −306.5% |
| Stock pay / revenue | 8.5% | 335.9% | 17.1% | 149.8% | 131.4% | 66.4% | 19.2% |
| Change in share count | 73.3% | 216.3% | 20.3% | 30.7% | — | 90.7% | 8.3% |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Grant | $3.5M | 100.0% | ▼ 46.2% |
| Cancer Prevention and Research Institute of Texas Acute Myeloid Leukemia (part of Grant) | $900,014 | 25.4% | ▼ 79.6% |
| National Institutes of Health Small Business Innovation Research For Lymphoma Grant (part of Grant) | $665,000 | 18.7% | 0.0% |
| Cprit Pancreatic Grant (part of Grant) | $573,994 | 16.2% | — |
| National Institutes of Health Small Business Innovation Research (part of Grant) | $472,208 | 13.3% | ▼ 51.9% |
| National Institutes of Health Small Business Innovation Research For Pancreatic Cancer (part of Grant) | $425,670 | 12.0% | ▲ 5831.0% |
| National Institutes of Health National Cancer Institute Grant (part of Grant) | $391,305 | 11.0% | ▲ 6621.1% |
| Fda Grant (part of Grant) | $118,478 | 3.3% | ▼ 77.2% |
From Marker Therapeutics, Inc.'s 10-K filed March 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Nea Management Company, LLC | $2.4M | 1.6M | 40.9% | 0.0% |
| Blue Owl Capital Holdings LP | $814,748 | 554K | 14.0% | 0.0% |
| Vanguard Capital Management LLC | $626,468 | 426K | 10.7% | ▲ 9.5% |
| Aisling Capital Management LP | $478,293 | 325K | 8.2% | 0.0% |
| Renaissance Technologies LLC | $366,652 | 249K | 6.3% | ▲ 42.3% |
| Geode Capital Management, LLC | $205,558 | 140K | 3.5% | ▼ 13.1% |
| Osaic Holdings, Inc. | $165,590 | 113K | 2.8% | ▲ 21.0% |
| Vanguard Fiduciary Trust Co | $128,285 | 87K | 2.2% | 0.0% |
| LPL Financial LLC | $122,226 | 83K | 2.1% | ▲ 0.1% |
| Concurrent Investment Advisors, LLC | $99,906 | 68K | 1.7% | New |
| Two Sigma Investments, LP | $88,495 | 60K | 1.5% | ▼ 1.3% |
| Xtx Topco Ltd | $66,675 | 45K | 1.1% | ▼ 28.6% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Marker Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around July 6, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
